[{"orgOrder":0,"company":"Hempstreet","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Curcumin","moa":"||PPA receptor-gamma","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Hempstreet \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hempstreet \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Hempstreet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Jatamansi","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hempstreet \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hempstreet \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Hempstreet

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : Sarpagandha Vati’s diuretic and detoxifying properties benefit people with lifestyle issues, epilepsy, delirium, anxiety disorder, curbs desire for alcohol and induces natural sleep to defy Insomnia.

                          Product Name : Sarpagandha Ghan Vati

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 23, 2022

                          Lead Product(s) : Sarpagandha,Jatamansi

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.

                          Product Name : CimetrA

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 05, 2022

                          Lead Product(s) : Curcumin,Boswellia Serata

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : MGC Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank